Bapineuzumab AD programme discontinued

Monday 6 August 2012

Johnson & Johnson Inc and Pfizer Inc have announced the termination of their jointly-run investigation of the drug, bapineuzumab, for patients with mild-to-moderate Alzheimer’s disease. This follows the failure of two Phase 3 studies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States